In context
Research, regulation, safety and market around peptides - briefly contextualized and sourced.
48 posts ·continuously updated ·independent & ad-free
Symbolic image Collagen peptides are booming: the market reaches $2.8B in 2026, driven by GLP-1 users seeking to prevent muscle loss and skin sagging. Manufacturers like Rousselot develop targeted products
Symbolic image An AI-powered nutrition study reveals 88% of GLP-1 users don't meet protein recommendations - averaging just 0.6 g/kg/day instead of the recommended 1.2-1.6 g/kg. Presented at the European Congress on Obesity 2026
Symbolic image The LEAN-PREP study systematically investigates whether resistance training and increased protein intake can prevent muscle loss on semaglutide and tirzepatide. Early data shows muscle can be preserved with the right strategy
Symbolic image The FDA plans a second PCAC meeting by February 2027 reviewing five more peptides, including injectable GHK-Cu and Melanotan II. All five were removed from Category 2 on April 22, 2026
Symbolic image FDA scientists recommend rejecting seven peptides - including BPC-157 and TB-500 - for US pharmacy compounding. The PCAC meeting takes place on July 23-24, 2026 in Silver Spring
Symbolic image Australia's TGA and Chief Medical Officer jointly warned on 19 June 2026 about serious harms from five unapproved peptides. Reports document liver damage, severe allergic reactions, and hospitalisations linked to BPC-157, GHK-Cu
Symbolic image A new Harvard-reviewed analysis shows 1 in 7 GLP-1 users develops vitamin D deficiency within a year. Iron and B vitamins are also affected - and protein needs rise to 1.2-1.6 g/kg
Symbolic image The peptide boom is creating its own food category: GLP-1 companion nutrition. Danone launched first products, the market is projected to grow from $3.1B to $15.4B
Symbolic image UK regulators seized around 12,000 unlicensed peptide weight-loss doses on May 28, 2026, the MHRA's largest raid ever. Substances included retatrutide and tirzepatide
The Peptide Signal - monthly, ad-free Learn more